骨髓增生异常综合征血管内皮生长因子表达与疾病进展的关系

The relationship between VEGF expression and disease progression of myelodyplastic sydrome and its treatment effect

目的:探讨骨髓增生异常综合征(myelodyplastic sydrome,MDS)患者血清血管内皮生长因子(vascular endothe-lial growth factor,VEGF)表达水平与病情进展和近期疗效的关系。方法:采用酶联免疫吸附法(enzyme-linked immunosorbent assay,ELISA)定量检测了17例MDS亚型中难治性贫血伴原始细胞增多型(refractory anemia with excess blasts,RAEB)患者初诊时、转化白血病后及治疗后血清VEGF水平。结果:17例初诊MDS-RAEB患者VEGF水平明显高于正常人组(P<0.05),转化白血病后其水平进一步增高(P<0.05),9例患者经治疗取得缓解后其水平明显下降(P<0.05)。结论:MDS-RAEB患者血清VEGF水平与病情进展、近期疗效密切相关,可作为判断预后和疗效的参考指标。

Objective： To study the relationship between expression of vascular endothelial growth factor （VEGF） in serum and disease progression and its treatment effect in myelodyplastic syndrome patients. Methods： We detected VEGF levels using enzyme-linked immunosorbent assay （ELISA） at the beginning of diagnosed, transferred into leukemia and acquired complete remission （CR） after treated in 17 cases with myelodyplastic syndrome with refractory anemia with excess blasts. Results： VEGF average levels of 17 patients in MDS-RAEB with firstly diagnosed higher than that in control group （P〈0.05）. It was much higher when these patients were transferred into leukemia. VEGF levels were decreased in 9 cases with acquired complete remission （CR） after treated （P〈0. 05）. Conclusion： There is an intimate relationship between VEGF expression and disease progression. The recent treatment effect in MDS-RAEB patients and VEGF levels in serum can be used as a reference index for diagnosis and treatment effect.